The American Society of Nuclear Cardiology (ASNC) says positron emission tomography (PET) nuclear imaging has seen wider adoption in the past few years, and many cardiac imaging experts say it could become the workhorse technology for nuclear cardiac assessments over the next decade. 

The team hopes to develop a model that will estimate a patient's risk of major cardiovascular events and predict when such events are most likely to occur.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

The cardiac radiologist and associate professor at the University of Toronto offered insights into key themes from the conference. 

Two renowned cardiologists are teaming up to explore the short- and long-term impact of using advanced AI platforms to evaluate coronary CCTA results for signs of coronary artery disease. 

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Ultromics designed EchoGo Amyloidosis to evaluate routine echocardiogram results for signs of cardiac amyloidosis. It received the FDA's breakthrough device designation back in 2023.